sEH-deficient mice show protection in animal models of inflammation, hypertension, and ischemia, which resulted in the development of sEH inhibitors for treatment of human cardiovascular diseases and pain (6, 7). This evidence concerns the gene EPHX2 and hypertensive disorder.